Rare disease drug development presents a unique paradox. Scientific innovation is advancing rapidly, yet clinical development remains extraordinarily challenging. Small patient populations, heterogeneous disease presentation, limited published data, and evolving regulatory expectations create significant uncertainty for emerging biopharma companies trying to move programs efficiently toward approval.
In this environment, understanding disease natural history has become a strategic foundation for successful rare disease development. Well-designed natural history studies can provide the evidence needed to address critical gaps in that understanding.
For small and mid-size biopharma sponsors, these studies can help reduce development risk, strengthen regulatory strategy, improve trial feasibility, and generate the evidence needed to support meaningful clinical outcomes.
What Is a Natural History Study?
A natural history study is an observational study designed to understand how a disease progresses over time in the absence of intervention or under standard of care. These studies may collect longitudinal clinical data, biomarker information, functional assessments, and patient-reported outcomes to better characterize the disease and its impact on patients.
Natural history studies can be retrospective, drawing on existing medical records, or prospective, collecting data according to a predefined protocol and visit schedule. They can also be cross-sectional, capturing a single point in time, or longitudinal, following the same patients over time. Retrospective chart reviews are faster and less expensive but are limited by missing and inconsistently recorded data, while prospective longitudinal designs take longer but are generally better suited to supporting regulatory decisions.
In common diseases, sponsors can often rely on decades of published literature and large datasets to guide development decisions. Rare diseases seldom offer that advantage. Many conditions are highly heterogeneous, meaning disease symptoms can vary dramatically between patients. Some diseases lack clearly defined progression markers altogether, while others have no validated endpoints accepted by regulators.
For many sponsors, the challenge is not simply developing a therapy but understanding how to measure whether that therapy is making a meaningful difference. Natural history studies help establish that context by identifying clinically relevant changes over time and clarifying which outcomes matter most to patients, caregivers, clinicians, and regulators.
As a result, these studies increasingly influence decisions across the entire development lifecycle.
Why Natural History Studies Matter in Rare Disease Development
Rare disease trials operate under constraints that are very different from those in more common diseases. Patient populations are often geographically dispersed, diagnosis may occur late in disease progression, and many diseases lack validated clinical endpoints.
Natural history studies help address these challenges by generating the data needed to make informed development decisions.
Informing Smarter Trial Design
One of the most immediate benefits of a natural history study is its ability to improve the design of future interventional trials. Natural history data help sponsors better understand disease progression and variability, which in turn informs endpoint selection, eligibility criteria, study duration, and patient stratification strategies. Natural history studies have also become increasingly important in cell and gene therapy development, where single-arm trials are common and robust external comparator data may be critical for interpreting treatment effects.
Without this foundational knowledge, sponsors may rely on assumptions that later create operational or regulatory challenges. Protocol amendments, endpoint revisions, and recruitment difficulties can all delay timelines and increase costs. By contrast, a well-designed natural history study can reduce uncertainty early and help sponsors build more targeted, efficient development programs.
Supporting Regulatory Strategy
Regulators recognize the value of natural history data in rare disease programs, especially when conventional clinical trial designs are difficult to implement. Natural history studies can play an important role in regulatory planning and evidence generation throughout rare disease development.
In the US, FDA’s draft guidance, Rare Diseases: Natural History Studies for Drug Development (2019), recognizes that natural history information is often incomplete in rare diseases and that natural history studies can inform patient population and eligibility criteria, endpoint selection, study duration, and the interpretation of treatment effects. In appropriate circumstances, natural history data may also contribute to an external control. In the EU, natural history data may help characterize disease severity, progression, and unmet need relevant to orphan drug development.
However, regulatory utility depends heavily on study quality. Agencies expect rigor in study design, consistency in data collection, and clear methodologies for minimizing bias. Sponsors that engage regulators early in the process and plan natural history studies strategically are often better positioned to ensure that their natural history data will ultimately support future clinical and regulatory milestones.
The Growing Role of External Control
As interest in innovative trial designs grows, natural history studies are also playing an increasingly important role in the development of external and synthetic control arms.
In many rare diseases, placebo-controlled trials can be ethically or operationally difficult. Patients and caregivers may be reluctant to participate in studies where treatment access is uncertain, particularly in progressive or life-limiting conditions. Natural history datasets may offer an alternative by providing comparator data that help contextualize treatment effects in smaller or single-arm studies.
Regulators have shown increasing openness to these approaches in select circumstances, but expectations remain high. The FDA approvals of cerliponase alfa for CLN2 disease (2017) and lonafarnib for progeria (2020), for example, relied on comparisons with natural history cohorts, and the 2023 approval of omaveloxolone for Friedreich’s ataxia used a propensity-matched comparison with natural history data as confirmatory evidence. Data quality, patient comparability, consistency of assessments, and statistical methodology all influence whether external control data will be considered reliable and fit for purpose. External controls are generally most persuasive when the natural history of the disease is well defined, the expected treatment effect is large, and endpoints are objective, such as survival. Because of this, sponsors considering future external control strategies must think carefully about how natural history studies are designed from the beginning.
Advancing Patient-Centric Drug Development
Natural history studies also provide a valuable opportunity to better understand the lived experience of patients and caregivers. In many rare diseases, traditional clinical assessments do not fully capture the outcomes that matter most to families navigating these conditions every day.
Longitudinal observational research can help identify meaningful functional changes, symptom burdens, and quality-of-life impacts that may otherwise be overlooked in interventional studies. These insights can ultimately shape endpoint development and contribute to more patient-centric trial designs.
Equally important, natural history studies often strengthen relationships with patient advocacy organizations and rare disease communities. These partnerships can become essential throughout the broader development process, particularly when addressing recruitment challenges or maintaining long-term patient engagement. In rare disease research, trust and collaboration are often just as important as scientific expertise.
Beyond Rare Disease: Natural History Studies in Common Diseases
Natural history studies are most closely associated with rare diseases, but the approach is just as useful wherever a disease is not understood well enough to design an efficient trial. Some of the most influential natural history studies were conducted in common diseases: the Framingham Heart Study, launched in 1948, helped establish high blood pressure and cholesterol as cardiovascular risk factors. Today, natural history data support development in common diseases in several ways.
Early and Presymptomatic Disease
As development moves toward treating disease before symptoms appear, sponsors need to know who will progress, and how fast. The Alzheimer’s Disease Neuroimaging Initiative (ADNI), a longitudinal observational study launched in 2004, helped refine the imaging and cognitive endpoints now routinely used in Alzheimer’s trials, and its data contributed to a disease progression model for trial simulation that FDA and EMA endorsed in 2013. In type 1 diabetes, observational cohorts, including TrialNet’s Pathway to Prevention study, helped define the presymptomatic stages of the disease. EMA qualified islet autoantibodies as enrichment biomarkers for prevention trials in 2022, the same year FDA approved teplizumab to delay the onset of clinical (stage 3) type 1 diabetes.
Biomarkers and Surrogate Endpoints
In heterogeneous diseases, natural history cohorts show which patients progress and which measures predict outcomes. Data from the observational Parkinson’s Progression Markers Initiative (PPMI), together with clinical trial data, supported EMA’s 2018 qualification of dopamine transporter imaging as an enrichment biomarker for early Parkinson’s disease trials, and FDA qualified plasma fibrinogen as a prognostic enrichment biomarker in COPD based primarily on data from the ECLIPSE observational cohort. In metabolic dysfunction-associated steatohepatitis (MASH), longitudinal cohorts showing that fibrosis stage predicts liver-related outcomes and mortality support the use of liver histology as a surrogate endpoint reasonably likely to predict clinical benefit, the basis for FDA’s accelerated approvals of resmetirom (2024) and semaglutide (2025).
Rare Subgroups Within Common Diseases
Biomarker-defined cancers, genetic subtypes, and pediatric populations often face the same constraints as rare diseases, even when the overall condition is common. In 2019, FDA extended palbociclib’s breast cancer indication to men, a small population within a common disease, with support from real-world data. In pediatrics, ICH E11A asks sponsors to assess whether the disease and its progression are sufficiently similar in children and adults before extrapolating efficacy, a question that pediatric natural history data can help answer.
More Efficient Randomized Trials
Even where randomized trials remain the standard, historical control and natural history data can make them more efficient. In 2022, EMA qualified prognostic covariate adjustment (PROCOVA), a method that uses a prognostic score built from historical data to increase the precision of treatment effect estimates in phase 2 and 3 trials with continuous outcomes, which can reduce the number of participants needed.
Where a common disease is already well characterized, with validated endpoints and extensive trial data, a new natural history study rarely adds value, and existing cohorts, registries, and real-world data may be sufficient. In every disease area, the underlying question is the same: is the course of the disease understood well enough to design, and later interpret, the pivotal trial?
Common Challenges in Natural History Studies for Rare Diseases
Despite their value, natural history studies are not without operational and scientific challenges.
Patient Recruitment and Retention
Rare disease populations are often small and geographically dispersed. Patients may also face mobility limitations, travel burdens, delayed diagnosis, or limited access to specialist centers, all of which can make enrollment and long-term follow-up difficult. These challenges can compound over time, making retention especially difficult in studies that span multiple years.
Data Variability and Standardization
Historical and observational datasets often contain inconsistencies across sites, clinicians, and assessment methodologies.
Sponsors must consider:
- Standardization of assessments
- Data harmonization strategies
- Centralized review processes
- Longitudinal consistency
Without sufficient rigor, data utility may be limited for future clinical trials and drug development.
Sponsors should also anticipate changes in the standard of care. Once a disease-modifying therapy becomes available, untreated natural history data become harder to collect, and historical cohorts may no longer reflect current clinical practice.
Regulatory Expectations
While regulators value natural history data, they also expect transparency, methodological rigor, and clear justification for how the data will be used.
Studies intended to support external controls or regulatory decision-making require particularly careful planning around:
- Bias mitigation
- Data provenance
- Endpoint consistency
- Statistical analysis plans
- Data standards and regulator access to patient-level data
Best Practices for Designing a High-Value Natural History Study
The most effective natural history studies begin with a clear understanding of how the data will ultimately be used. Sponsors should define early whether the study is intended to support endpoint development, future interventional trial design, regulatory engagement, or external control strategies. Establishing these objectives upfront helps ensure that the study generates data that are both relevant and actionable.
Early regulatory engagement is equally important. Discussions with agencies can help align expectations around study methodology, endpoint selection, and future applications of the dataset. This alignment may reduce downstream development risk and improve confidence in the long-term utility of the study.
FDA guidance documents Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products (2023) and Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products (2024) reflect the increasing role of registries and other real-world data sources, including electronic health records, in supporting regulatory decision-making across therapeutic areas, not only in rare disease and cell and gene therapy programs. When thoughtfully integrated with natural history studies and clearly defined objectives, well-curated registries can deepen the understanding of disease progression, patient heterogeneity, long-term outcomes, and treatment patterns. Importantly, the regulatory value of these data depends on whether they are fit for purpose for the specific question being addressed.
Patient involvement should also play a central role in study planning. Advocacy groups, caregivers, and patients themselves can provide valuable insight into meaningful outcomes, feasible assessment schedules, and participation burden. Incorporating these perspectives early often improves both study quality and long-term retention.
Operational rigor remains critical throughout execution. Standardized assessments, centralized oversight, robust data governance, and audit-ready systems all contribute to higher-quality longitudinal datasets. Increasingly, sponsors are also incorporating decentralized and hybrid approaches, including remote assessments, wearable technologies, and electronic patient-reported outcomes, to reduce patient burden and improve participation. Wearables can also generate new endpoints: stride velocity 95th centile, measured with a wearable sensor and supported in part by natural history data, became the first digital measure qualified by EMA as a primary endpoint in any disease (Duchenne muscular dystrophy, 2023).
Ultimately, the highest-value natural history studies are those designed not only to collect data, but to support broader development strategy.
The Regulatory Landscape for Natural History Studies
Because natural history studies are observational, the regulatory requirements for starting one are lighter than for an interventional trial. The requirements that determine whether the resulting data will be accepted as evidence, however, are becoming more detailed.
Study Start-Up: Ethics Review Rather Than a Clinical Trial Application
In the US, the FDA states that non-interventional studies are not clinical investigations under its IND regulations and do not require an IND. A natural history study still needs IRB approval and informed consent (or an IRB-approved waiver), and the FDA notes that many natural history studies may qualify for expedited IRB review and encourages the use of a single IRB across sites. In the EU, non-interventional studies fall outside the Clinical Trials Regulation (EU) No 536/2014, so there is no clinical trial application through CTIS. National rules apply instead: an ethics committee opinion is usually required, some countries also require notification or registration, and the processing of health data must comply with the GDPR. In the UK, Health Research Authority (HRA) approval and, typically, research ethics committee review are needed, but not an MHRA clinical trial authorization.
Start-up is therefore usually faster than for an interventional trial, but not automatically fast. Multi-country studies must navigate differing national ethics and data protection requirements, and protocols that include biological sampling, genetic testing, or children tend to receive closer review.
Guidance That Shapes Regulatory Acceptability
Whether natural history data can later support a regulatory decision depends on how the study was designed, conducted, and documented. Key references include:
- FDA: draft guidances on rare disease natural history studies (2019), externally controlled trials (2023), and non-interventional studies (2024), plus final guidances on real-world data and evidence (2023–2024)
- EMA: Guideline on Registry-Based Studies (2021), reflection papers on real-world data in non-interventional studies (2025) and on single-arm trials (2024), and a reflection paper on external controls that is in development
- ICH: E10 on the choice of control group (2000) and M14 on pharmacoepidemiological studies using real-world data (2025)
The expectations are consistent across these documents: a prespecified protocol and statistical analysis plan, fit-for-purpose data sources, consistent endpoint definitions, strategies to address bias and confounding, and access to patient-level data. FDA recommends that sponsors share draft protocols and statistical analysis plans with the Agency before conducting the analyses, and EMA encourages registering studies in the HMA-EMA real-world data catalogues.
Can Natural History Studies Speed Up Approval?
Natural history studies do not create a separate or faster approval pathway, but well-designed studies can shorten development and strengthen the case for expedited routes:
- Documenting disease severity, prevalence, and unmet need supports orphan designation and expedited programs such as Fast Track, Breakthrough Therapy, RMAT, and EMA’s PRIME scheme.
- Linking biomarkers or intermediate endpoints to clinical outcomes can support accelerated approval in the US and conditional marketing authorization in the EU.
- External controls and confirmatory evidence can reduce the size or number of trials. Under FDA’s Rare Disease Evidence Principles (2025), therapies for very small genetic diseases (generally fewer than 1,000 US patients) may be approved based on one adequate and well-controlled study plus confirmatory evidence, which can include external controls or natural history studies. More broadly, FDA has described one pivotal trial plus confirmatory evidence as its new default for approval, and its revised draft guidance on substantial evidence of effectiveness (2026) cites natural history data as one potential source of confirmatory evidence.
- For individualized genetic therapies, FDA’s draft plausible mechanism framework (2026) relies on a well-characterized natural history of the disease.
The reverse is also true: natural history data that are incomplete, collected inconsistently, or not comparable with the trial population can prolong reviews and prompt requests for additional data. Payers and health technology assessment bodies will scrutinize the same data, including in the new EU Joint Clinical Assessments, which extend to orphan medicines from 2028. Early alignment through FDA meetings, EMA scientific advice or protocol assistance, or MHRA scientific advice remains the most reliable way to ensure natural history data will count.
Why CRO Expertise Matters in Rare Disease Natural History Studies
Natural history studies require a unique combination of scientific expertise, operational execution, regulatory insight, and patient engagement capabilities. For small and mid-size biopharma companies with limited internal resources, the right CRO partner can play an important strategic role.
Experienced rare disease CROs understand the complexities of working within small patient populations and evolving regulatory frameworks. They can help sponsors design studies that align with future clinical objectives, identify operational risks early, and implement data collection strategies capable of supporting long-term development goals.
That expertise is also important when a natural history study is used to inform operational feasibility. Beyond characterizing disease progression, these studies can help sponsors understand where patients are treated, how they move through referral pathways, which centers may have access to the target population, and whether proposed assessments and visit schedules are feasible for patients and caregivers. These insights can substantially strengthen site selection, recruitment assumptions, and retention strategies for the subsequent interventional program.
This experience becomes especially important in rare disease programs where timelines are compressed and opportunities to gather high-quality longitudinal data may be limited. A strategic CRO partner can help ensure that natural history studies generate meaningful value across the broader clinical development pathway rather than functioning as isolated research initiatives.
Conclusion
A robust understanding of disease natural history is a strategic foundation for rare disease development, and increasingly for common diseases as well. Natural history studies can provide a practical way to reduce uncertainty before pivotal decisions are made. By characterizing disease progression, identifying meaningful endpoints, clarifying patient availability, and strengthening regulatory discussions, these studies can help shape a more focused and credible development plan.
Sponsors planning a rare disease program should consider early whether a natural history study could address key development questions: Who are the right patients? Which outcomes will be meaningful and persuasive? What evidence will regulators need? Where are the recruitment and feasibility risks? Addressing these questions early can help reduce the risk of costly redesigns later.
The next step is to design natural history studies with the same strategic discipline as interventional trials: align objectives with the intended use of the data and the regulatory pathway, involve patients and advocacy groups from the start, and standardize data collection so that the data remain fit for regulatory use.
FAQs
Request a Proposal
Share This
